Loading
STK-012 is an experimental engineered immune-signalling protein from Synthekine, in phase 2 trials for non-small cell lung cancer.
STK-012 is an engineered cytokine (interleukin-2 partial agonist) from Synthekine. An alpha/beta-biased interleukin-2 partial agonist that preferentially stimulates antigen-activated T cells carrying the high-affinity IL-2 receptor, which includes CD25 (IL-2 receptor alpha) and IL2RB. The phase 2 part of NCT05098132 is in first-line PD-L1-negative non-squamous non-small cell lung cancer, with pembrolizumab, pemetrexed and carboplatin.
An alpha/beta-biased interleukin-2 partial agonist that preferentially stimulates antigen-activated T cells carrying the high-affinity IL-2 receptor, which includes CD25 (IL-2 receptor alpha) and IL2RB. Connects to CD25 (IL-2 receptor alpha) and IL2RB.
1.STK-012 binds CD25 (IL-2 receptor alpha).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"STK-012" OR ABSTRACT:"STK-012") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STK-012, not a curated reading list.
Shares CD25 (IL-2 receptor alpha), Non-small-cell lung cancer and the tag pipeline.
Shares CD25 (IL-2 receptor alpha) and the tag pipeline.
Shares CD25 (IL-2 receptor alpha) and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/